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Introduction
After a primary varicella infection (chickenpox), the
varicella zoster virus (VZV) can remain persistent
but clinically latent in the sensory nerve ganglia for
many years before being reactivated and becoming
manifest clinically as herpes zoster (HZ) or ‘shingles’
(1–4). HZ is characterised by a skin rash that is
localised to the sensory region of the affected ganglia
and is often preceded or accompanied by acute pain
or itching. Pain may persist for months or even
years, and this postherpetic neuralgia (PHN) is the
most common and debilitating complication of HZ.
There is currently no consensus deﬁnition for PHN.
However, data that identify three distinct phases of
pain (acute herpetic neuralgia, subacute herpetic
neuralgia and chronic pain or PHN) in HZ suggest
that PHN might be best deﬁned as pain lasting at
least 3 months after resolution of the rash (5–7).
PHN is associated with signiﬁcant loss of function
and reduced quality of life, particularly in the elderly
(8), and is highly resistant to treatment. Management
of PHN is currently limited to antiviral therapy
addressing the underlying cause (VZV infection) and
analgesics for the symptomatic treatment of acute
pain. This review focuses on the epidemiology, clini-
cal features, management and prevention of PHN in
the elderly.
Epidemiology of HZ and PHN
Herpes zoster is a relatively common condition; the
incidence of acute HZ in the general population
in Europe ranges from about 1.2 to 5.2 per 1000
person-years (annual events per 1000 population)
(9–15). There is a strong correlation between the
incidence of HZ and increasing age, with a marked
rise in incidence at the age of 50–60 years and older
(9,10,14). The lifetime risk of HZ is estimated to be
up to 25% in the general population, thus one in
four people may experience HZ in their lifetime.
This risk rises to 50% in those aged > 85 years
(16,17).
Herpes zoster is more common in individuals with
immunosuppression subsequent to HIV infection or
prophylaxis to avoid rejection of organ transplants,
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SUMMARY
Postherpetic neuralgia (PHN) is the most common complication of herpes zoster
(HZ) or ‘shingles’ and affects a signiﬁcant proportion of HZ patients with the dis-
ease, with the elderly being most frequently and seriously affected. Characterised
by various types of pain (constant, intermittent and stimulus evoked) that persist
between 3 months and many years after the resolution of the HZ rash, PHN can
have a severe impact on the patient’s quality of life and functional ability. PHN
remains highly resistant to current treatments. In this review, we discuss the epide-
miology, clinical features and management of PHN in the elderly and the potential
of vaccination against varicella zoster virus as a means to prevent HZ, and thus
decrease the incidence and severity of PHN.
Review Criteria
Information on postherpetic neuralgia was gathered
via a search for relevant primary and review
literature in the PubMed database using the search
terms ‘postherpetic neuralgia’ or ‘PHN’, and a wide
variety of key areas of interest (e.g. ‘epidemiology’,
‘management’ and ‘pain’). This was then
supplemented by references found within relevant
selected papers and by the clinical experience of
the authors.
Message for the Clinic
Postherpetic neuralgia (PHN), the most common
complication of herpes zoster, may have a serious
impact on quality of life and functional ability,
particularly in the elderly. More effective therapies
are needed as PHN is often refractory to current
clinical management strategies. A prophylactic
vaccine against varicella zoster virus represents a
promising clinical approach to limit the
debilitating complications of herpes zoster,
including PHN.
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1386 doi: 10.1111/j.1742-1241.2009.02089.xcertain malignancies or treatment thereof, or treat-
ment for inﬂammatory or autoimmune disease (18).
Of patients with HZ, approximately 14% will
develop complications, the most common of which
is PHN. Estimates of the prevalence of PHN vary
widely depending upon the deﬁnition of PHN used,
the study methodology and the study population.
PHN persisting at 3 months may occur in 10–20%
of HZ patients aged > 50 years (15,19–21). Other
less frequently occurring complications may be neu-
rological (e.g. anaesthesia in the affected dermatome,
motor paresis), ophthalmic (e.g. pan ophthalmitis,
keratitis, scleritis, uveitis and loss of corneal sensa-
tion), cutaneous (e.g. scarring, bacterial superinfec-
tions of HZ lesions), visceral, or may involve
systemic dissemination of the virus (e.g. cerebral vas-
culitis, pneumonia) (22,23).
Age is the predominant predictor of PHN (24,25).
In a UK primary-care study, the prevalence of PHN
(3-month deﬁnition) increased markedly with age:
from 8% at age 50–54 years to 21% at age 80–
84 years (15). Other risk factors for PHN include
prodromal pain, severe acute pain, rash severity and,
in some cases, concomitant disease (26,27). There is
also evidence that PHN is more common in women
than in men (15,28).
Throughout Europe, the elderly population is
expanding rapidly: it is estimated that by 2040 the
population aged > 80 years will have doubled to
almost 10% of the total population (29). An upward
trend in the incidence of HZ and particularly in
PHN that has already been observed is thus expected
to continue (30). As it is the elderly who sustain the
greatest burden caused by PHN, in terms of pain
and suffering as well as medical costs (31), this
demographical shift will represent a considerable
burden on the healthcare and social system.
Clinical features of PHN
Postherpetic neuralgia can manifest as different kinds
of pain. It may present as constant pain, character-
ised by burning, aching or throbbing; as intermittent
pain, including stabbing and shooting pain; or as
stimulus-evoked pain, such as allodynia (the experi-
encing of pain after a normally non-painful stimulus,
such as a cold breeze or a light touch from clothing)
(16).
While PHN will resolve in most cases, it may per-
sist in some patients for an extended period. A long-
term study demonstrated that 9% (11 out of 12 of
whom were aged > 51 years) still had pain at 1 year
after resolution of the rash (32). In a recent rando-
mised, double-blind, placebo-controlled, multi-centre
study in the USA, the Shingles Prevention Study, in
the placebo group, in people aged ‡ 60 years, 80 out
of 642 (12.4%) had PHN at 3 months and in 41% of
these cases PHN persisted for at least 182 days (19).
Other studies have reported that PHN can last for
years (21).
The negative impact of PHN on the quality of life
can be similar to that caused by life-threatening dis-
eases or serious psychological conditions. PHN can
have a signiﬁcant effect on many aspects of a
patient’s life, causing chronic fatigue, sleep disorders,
difﬁculty in concentrating, depression and anxiety,
anorexia, loss of bodyweight and social isolation
(33,34). PHN can interfere with basic and essential
activities of daily living, such as dressing, bathing,
mobility, travelling, shopping, cooking and house-
work, thus considerably impairing an individual’s
functional ability and, in some cases, causing an
active member of the community to become rela-
tively inactive and housebound (16,34). The more
severe the pain experienced, the more signiﬁcant the
impact on quality of life; in a study of 50 patients
with HZ, those with pain scores ‡ 4 out of 10 expe-
rienced the greatest interference with daily living,
including general activity, work, sleep and enjoyment
of life (35).
With more than 20% of the population of the
European Union already aged > 60 years (36) and
continuing increases in life expectancy predicted,
attention is being focused on the concept of ‘healthy
aging’. Prevention of HZ and the disability associated
with PHN would help people to remain active in old
age, compressing the period of senescence to nearer
the end of life (37,38).
Management of HZ and PHN
The delayed or atypical presentation of HZ often
prevents timely treatment; studies suggest that only
25–50% of patients may receive antivirals at an early
stage (32,39). Antiviral agents (acyclovir, valaciclovir,
famciclovir and brivudin) can alleviate acute pain
and reduce the risk of long-term pain in patients
with HZ (40); however, it is unclear to what extent
they reduce the incidence of prolonged PHN. Corti-
costeroids, given either orally (41,42) or as a single
epidural injection (43), have also shown beneﬁcial
effects on acute pain, but they do not prevent PHN
(44).
Optimal pain control is difﬁcult to achieve with
currently available medications, and no single treat-
ment is completely effective for all patients; in clini-
cal practice, the combinations of analgesic drugs
used usually only achieve partial pain relief (45).
Moreover, the complex and heterogeneous nature of
the mechanisms that contribute to PHN suggest that
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(46). The beneﬁts and disadvantages of the main
PHN therapies are summarised in Table 1.
A recent meta-analysis has demonstrated evidence
of analgesic efﬁcacy in established PHN for several
orally administered therapies: tricyclic antidepressants
(TCAs), opioids (including tramadol) and anticon-
vulsants (gabapentin and pregabalin) (45). TCAs and
gabapentin are recommended as ﬁrst-line therapy for
this condition, being almost equally efﬁcacious in the
Table 1 The beneﬁcial effects and potential limitations of common treatments for postherpetic neuralgia
Class References Treatment Beneﬁts Limitations
Systemic
Tricyclic
antidepressants
45–48 In general Effect on pain Poor AE proﬁle: anticholinergic AEs (drowsiness, dry
mouth, constipation, increased appetite)
Rare: blurred vision, urinary retention, glaucoma
exacerbation, mood change
Amitriptyline Effect on pain in some patients
Nortriptyline Effect on pain in some patients
Desipramine Less sedating than other TCAs.
Less toxic side effect proﬁle than
amitriptyline
Maprotiline Effect on pain in some patients Lower efﬁcacy than amitriptyline, poor side effect proﬁle
Anticonvulsants 40,45,47,48 Gabapentin Higher beneﬁt-to-AE ratio than TCAs.
Effect on pain, sleep interference,
positive effect on mood, QoL
AEs: somnolence, dizziness, ataxia, peripheral oedema,
infection (all usually minor)
Caution required in patients with myasthenia gravis or
impaired renal function
Pregabalin Effect on pain, sleep Mild-to-moderate dizziness, somnolence, headache,
dry mouth
Carbamazepine Little⁄no pain beneﬁt
Confusion and sedation in elderly patients
Lamotrigine Some evidence of neuropathic
pain beneﬁt
Dermatological complications more severe than other
drugs in this class
Opioids 40,45,47,48 In general Effect on pain. May be preferable
to TCAs
Stronger opioids are recommended to be administered
in a specialist clinic only and are therefore
not ﬁrst-line therapy
AEs: respiratory depression, constipation, sedation,
nausea, vomiting, delirium, dependence
Morphine Effect on pain
Oxycodone Effect on pain
May provide signiﬁcant pain relief
Levorphanol Effect on pain
Tramadol May provide satisfactory pain relief Cannot be administered with antidepressants
NMDA antagonists
(antagonists of the
N-methyl d-aspartate
receptor)
45,47,48 Ketamine May be effective in some patients
(poor evidence available)
AEs: itching, painful induration at injection site,
nausea, fatigue, dizziness, psychodysleptic⁄cognitive
effects
Dextromethorphan Not effective in PHN
Amino-amide 45,48 i.v. Lidocaine No signiﬁcant effect on pain
AEs: mild nausea, light-headedness
Topical
Amino-amide 47,48 Lidocaine
5% patch
Effect on pain
May be beneﬁcial in allodynia
Minimal systemic uptake
Available in self-adhesive patch
Some local irritation possible
Capsaicinoid 45,48 Capsaicin Effect on pain Pungent
Burning sensation
AE, adverse event; QoL, quality of life; TCA, tricyclic antidepressant; NMDA, N-methyl-D-aspartate; PHN, postherpetic neuralgia.
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associated with more minor adverse events than
gabapentin and are more likely to interact with other
drugs (48), a particular concern in elderly patients
who are likely to be using concomitant medications
for chronic diseases. Pregabalin, an analogue of gaba-
pentin, has been shown to signiﬁcantly decrease pain
and improve sleep in randomised, placebo-controlled
trials (49,50). Although opioids also appear to be
effective in controlling neuropathic pain, the age and
frailty of the patient limit the prescription of such
drugs known to produce moderate-to-severe side
effects such as nausea and constipation (40).
Topical application of lidocaine is a well-tolerated
supplementary treatment for PHN, and patches con-
taining lidocaine are an approved treatment in the
United States and Europe (51,52). There is conﬂict-
ing evidence for the use of topical lidocaine (patches
or gel) or a eutectic mixture of local anaesthetics
(EMLA
 , AstraZeneca, Miami, FL, USA) in the treat-
ment of PHN with allodynia; while a recent system-
atic review found insufﬁcient evidence to support its
use (53). Previous reviews have concluded that lido-
caine should be a ﬁrst-line adjunctive treatment in
this context (45,52,53). The topical use of capsaicin
has been shown to provide signiﬁcant pain relief in
two randomised trials, although patient response can
be delayed and discomfort and burning sensations
can limit compliance (45,53).
While not supported by evidence from randomised
clinical trials, some clinicians treat PHN with periph-
eral, epidural, intrathecal or sympathetic nerve block-
ade with local anaesthetics and⁄or steroids. Such
interventions have also been used in the treatment of
HZ, but results for the prevention and treatment of
PHN have been disappointing as only short-term
analgesic effects have been demonstrated (43,54,55).
Two studies on intrathecal or epidural administra-
tion of methylprednisolone with or without lidocaine
(56,57) appear to show considerable efﬁcacy in the
intrathecal groups, although the safety of this tech-
nique remains uncertain (58). Until these studies
have been replicated, such treatment cannot be
recommended.
Non-pharmacological treatments for PHN include
transcutaneous electrical nerve stimulation, acupunc-
ture and other alternative therapies. While the effec-
tiveness of such interventions has not been
adequately investigated, the low risks associated with
their use suggest that they may be considered in
combination with conventional treatment or in older
patients who fail to respond to ﬁrst-line treatments
(52). Behavioural therapies such as relaxation tech-
niques have been used with positive effects (52), and
the potential beneﬁts of psychological support for
depression and pain-management strategies should
not be ignored (54).
Currently available treatments are thus of limited
efﬁcacy and are associated with adverse events that
are poorly tolerated, especially by elderly patients.
There is a need for long-term randomised-controlled
clinical trials to assess the efﬁcacy of combinations of
medications and new therapies (59).
Prevention of PHN
The increased risk and severity of HZ and PHN with
advancing age are associated with an age-related
decline in VZV-speciﬁc T-cells (16). VZV-speciﬁc
T-cell immunity could eventually fall to below a
threshold at which symptomatic VZV reactivation is
likely to occur, thereby increasing the risk of HZ
(60). A prophylactic vaccine that can increase VZV-
speciﬁc T-cell immunity represents a promising clini-
cal approach to limit the debilitating complications
of HZ, including PHN (16,60,61). Indeed, HZ itself
is associated with an increase in VZV-speciﬁc T-cells,
and recurrences of HZ in immunocompetent indi-
viduals are rare (22,60). In the Shingles Prevention
Study, the efﬁcacy of a live attenuated Oka⁄Merck
VZV vaccine in decreasing the incidence and⁄or
severity of HZ and PHN was evaluated in a trial
involving 38,546 individuals aged ‡ 60 years (19).
End-points included burden of illness (BOI) due to
HZ, a measure reﬂecting the incidence, severity and
duration of HZ-associated pain and discomfort (pri-
mary end-point) (19) and the incidence of HZ and
PHN.
Vaccination markedly decreased both the morbid-
ity associated with HZ and the incidence of PHN for
a mean duration of at least 3 years (19,62). The BOI
of HZ was signiﬁcantly reduced in vaccine-recipients
(61% reduction, p < 0.001 vs. placebo), and a signif-
icant reduction in the incidence of PHN at 3 months
(67% reduction; p < 0.001 vs. placebo) was observed
(19). Efﬁcacy against HZ, a secondary end-point, was
51% (p < 0.001 vs. placebo). Although HZ vaccine
efﬁcacy was greater at age 60–70 years (64%) than at
age > 70 years (38%), efﬁcacy for reducing HZ BOI
and PHN was similar in both age groups (19).
The vaccine was safe and well tolerated. There was
no difference in overall mortality between the vaccine
and placebo groups. The most commonly observed
adverse events observed in the Shingles Prevention
Study occurred at the local injection site (48% in
vaccine-recipients vs. 16% in placebo-recipients;
p < 0.05), while systemic adverse events occurred in
6.3% of vaccine-recipients and 4.9% of placebo-
recipients (p < 0.05); headache being the most
frequent reported (19).
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Station, NJ) has been approved by the US Food and
Drug Administration and by the European Medicines
Agency. It is indicated for the prevention of HZ in
individuals aged 60 years (US) or 50 years (EU) and
older and is contraindicated in immunocompro-
mised patients, children and pregnant women.
Recent studies indicate that vaccination of an aged
population is likely to be cost-effective from the
healthcare-payer perspective (63).
Conclusion
HZ and associated PHN can have a considerable
impact on quality of life. PHN can be debilitating
for some patients and may be a signiﬁcant contribut-
ing factor to the progression of disability in older
people. PHN is difﬁcult to treat and is often refrac-
tory to traditional therapeutic approaches and stan-
dard analgesic regimens. More effective strategies for
the management of HZ and related pain are essen-
tial. The prevention of HZ by vaccination has the
potential to reduce the incidence and severity of
PHN.
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